These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29075265)

  • 1. KIR3DS1/HLA-B Bw4-80Ile Genotype Is Correlated with the IFN-α Therapy Response in hepatitis B e antigen-Positive Chronic Hepatitis B.
    Li W; Shen X; Fu B; Guo C; Liu Y; Ye Y; Sun R; Li J; Tian Z; Wei H
    Front Immunol; 2017; 8():1285. PubMed ID: 29075265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of KIR-HLA genotype on hepatitis B virus clearance in Iranian infected individuals.
    Shah-Hosseini A; Jafari M; Mohammadi A; Sanaei R; Alavian SM; Doosti-Irani A; Nooradeh Keykavousi M; Tajik N
    Med Microbiol Immunol; 2017 Dec; 206(6):463-470. PubMed ID: 29032460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The favorable effects of KIR3DS1 and Bw4(80Ile) on viral set point and CD4 count decline in HIV-1 patients with acutely infected with HIV-1 infection].
    Wang R; Liu Y; Lu XF; Liu ZY; Li Z; Zhang X
    Zhonghua Yi Xue Za Zhi; 2018 Sep; 98(35):2819-2823. PubMed ID: 30248785
    [No Abstract]   [Full Text] [Related]  

  • 4. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS.
    Martin MP; Gao X; Lee JH; Nelson GW; Detels R; Goedert JJ; Buchbinder S; Hoots K; Vlahov D; Trowsdale J; Wilson M; O'Brien SJ; Carrington M
    Nat Genet; 2002 Aug; 31(4):429-34. PubMed ID: 12134147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KIR2DL3 and the KIR ligand groups HLA-A-Bw4 and HLA-C2 predict the outcome of hepatitis B virus infection.
    Di Bona D; Aiello A; Colomba C; Bilancia M; Accardi G; Rubino R; Giannitrapani L; Tuttolomondo A; Cascio A; Caiaffa MF; Rizzo S; Di Lorenzo G; Candore G; Duro G; Macchia L; Montalto G; Caruso C;
    J Viral Hepat; 2017 Sep; 24(9):768-775. PubMed ID: 28211154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-C and KIR combined genotype as new response marker for HBeAg-positive chronic hepatitis B patients treated with interferon-based combination therapy.
    Stelma F; Jansen L; Sinnige MJ; van Dort KA; Takkenberg RB; Janssen HL; Reesink HW; Kootstra NA
    J Viral Hepat; 2016 Aug; 23(8):652-9. PubMed ID: 26945896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KIR3DS1-Mediated Recognition of HLA-*B51: Modulation of KIR3DS1 Responsiveness by Self HLA-B Allotypes and Effect on NK Cell Licensing.
    Carlomagno S; Falco M; Bono M; Alicata C; Garbarino L; Mazzocco M; Moretta L; Moretta A; Sivori S
    Front Immunol; 2017; 8():581. PubMed ID: 28603523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KIR and HLA genotypes predictive of low-affinity interactions are associated with lower relapse in autologous hematopoietic cell transplantation for acute myeloid leukemia.
    Marra J; Greene J; Hwang J; Du J; Damon L; Martin T; Venstrom JM
    J Immunol; 2015 May; 194(9):4222-30. PubMed ID: 25810393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased interferon-γ production by NK cells from KIR haplotype B carriers in hepatitis C virus infection.
    Mele D; Pasi A; Cacciatore R; Mantovani S; Oliviero B; Mondelli MU; Varchetta S
    Liver Int; 2019 Jul; 39(7):1237-1245. PubMed ID: 31177636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KIR/HLA genotypes confer susceptibility and progression in patients with autoimmune hepatitis.
    Umemura T; Joshita S; Saito H; Yoshizawa K; Norman GL; Tanaka E; Ota M
    JHEP Rep; 2019 Nov; 1(5):353-360. PubMed ID: 32039386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-DP and γ-interferon receptor-2 gene variants and their association with viral hepatitis activity in chronic hepatitis B infection.
    Lam YF; Wong DK; Seto WK; To KK; Hung IF; Fung J; Lai CL; Yuen MF
    J Gastroenterol Hepatol; 2014 Mar; 29(3):533-9. PubMed ID: 23980639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.
    Sonneveld MJ; Rijckborst V; Zeuzem S; Heathcote EJ; Simon K; Senturk H; Pas SD; Hansen BE; Janssen HL
    Hepatology; 2012 Jul; 56(1):67-75. PubMed ID: 22307831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of HLA-DP and IL28B gene polymorphisms on response to interferon treatment in hepatitis B e-antigen seropositive chronic hepatitis B patients.
    Cheng L; Sun X; Tan S; Tan W; Dan Y; Zhou Y; Mao Q; Deng G
    Hepatol Res; 2014 Sep; 44(9):1000-7. PubMed ID: 24298935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-alpha treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan.
    Hsu HY; Tsai HY; Wu TC; Chiang CL; Ni YH; Chen PJ; Chang MH
    Liver Int; 2008 Nov; 28(9):1288-97. PubMed ID: 18397229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIR/HLA ligands immunogenetics markers associated with outcome of hepatitis B virus infection in the Bulgarian population.
    Varbanova V; Popov G; Grigorova V; Petrova D; Naumova E; Mihaylova A
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2021 Sep; 165(3):270-276. PubMed ID: 32975242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
    Buster EH; Hansen BE; Lau GK; Piratvisuth T; Zeuzem S; Steyerberg EW; Janssen HL
    Gastroenterology; 2009 Dec; 137(6):2002-9. PubMed ID: 19737568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.
    Tseng TC; Yu ML; Liu CJ; Lin CL; Huang YW; Hsu CS; Liu CH; Kuo SF; Pan CJ; Yang SS; Su CW; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2011; 16(5):629-37. PubMed ID: 21817184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P; Lenci I; Demelia L; Bandiera F; Piras MR; Antonucci G; Nosotti L; Mari T; De Santis A; Ponti ML; Sorbello O; Iacomi F; Angelico M
    Antivir Ther; 2009; 14(8):1165-74. PubMed ID: 20032546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.